MAIA Biotechnology's Ateganosine: A Promising Telomere-Targeting Therapy for Advanced NSCLC
MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company, is currently conducting a pivotal Phase 3 trial, THIO-104, to evaluate a novel telomere-targeting therapy as a third-line treatment for advanced non-small cell lung cancer (NSCLC). The trial has seen 29 patients dosed across 34 activated trial sites in six foreign countries, showing promising progress in patient enrollment.
Dr. Vlad Vitoc, the Founder and CEO of MAIA, expressed optimism about the Phase 3 study's advancement, aiming to enroll up to 100 patients by the end of the year. The company anticipates conducting an interim analysis in 2027 based on the survival data gathered from the trial.
MAIA's lead therapeutic, ateganosine, is a unique dual mechanism therapy designed to disrupt telomere structure in cancer cells and stimulate immune activation. With a median overall survival of 17.8 months observed in the Phase 2 trial, ateganosine presents a significant advancement compared to the standard chemotherapy treatment for 3L NSCLC patients, which typically results in a survival rate of 5.8 months.
The potential of ateganosine as a breakthrough therapeutic is underscored by its significant commercial opportunity in the projected $70 billion global NSCLC treatment market by 2030. The U.S. FDA has granted Fast Track designation for ateganosine as a third-line treatment for NSCLC, recognizing its potential impact on patient care.
Ateganosine, a first-in-class investigational telomere-targeting agent, is currently in clinical development for NSCLC. By inducing telomerase-dependent telomeric DNA modification and activating immune responses, ateganosine shows promise in selectively targeting cancer cells and promoting tumor regression. The therapy is being evaluated as a second or later line of treatment for NSCLC patients who have progressed beyond existing checkpoint inhibitors, offering new hope for improved outcomes in advanced lung cancer treatment.